New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.

@article{Inzucchi2008NewDF,
  title={New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.},
  author={Silvio E. Inzucchi and Darren K. McGuire},
  journal={Circulation},
  year={2008},
  volume={117 4},
  pages={
          574-84
        }
}
This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 83 CITATIONS, ESTIMATED 48% COVERAGE

Thiazolidinediones and Cardiovascular Risk — A Question of Balance

  • Current cardiology reviews
  • 2009
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1.

  • Therapeutic advances in cardiovascular disease
  • 2012
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 83 REFERENCES

: cause or consequence of the diabetic state ?

B Ahren
  • Diabetes .
  • 2007